CDH3

Across TCGA pan-cancer cohorts, CDH3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CDH3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where CDH3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CDH3 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LSCC, PDAC, and LUAD are the cancer types where CDH3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDH3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+1.282	<.001	9	view →
PDAC	All	III,IV	+1.065	<.001	9	view →
LUAD	All	III,IV	+0.703	<.001	9	view →
COAD	All	All	+0.710	<.001	8	view →
HNSC	Male	III,IV	+0.573	<.001	8	view →
CCRCC	Male	II,III,IV	−0.702	.015	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CDH3–LSCC

Open the LSCC breakdown →